FrancophonIA/ELRC3.0 huggingface dataset:
English: Adenuric should be started two days before chemotherapy and continued for at least 7 days.
Estonian: Ravi Adenuriciga tohib alustada kaks päeva enne keemiaravi ning jätkata vähemalt 7 päeva.
English: Attacks of gout can still occur during the first few months of treatment, so it is recommended that patients take other medicines to prevent attacks of gout for at least the first six months of treatment with Adenuric.
Estonian: Ravi esimestel kuudel võib veel tekkida podagrahooge, seega on patsientidel soovitatav kasutada vähemalt ravi esimese kuue kuu jooksul podagrahoogude ennetamiseks lisaks Adenuricile ka teisi ravimeid.
English: The main measure of effectiveness was the number of patients whose final three blood uric acid levels were below 6 mg/dl.
Estonian: Efektiivsuse põhinäitaja oli nende patsientide arv, kelle vere kusihappesisaldus oli kolmel viimasel mõõtmisel alla 6 mg/dl.
English: Adenuric febuxostat
Estonian: Adenuric febuksostaat
English: The Committee decided that Adenuric's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Adenurici kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Other information about Adenuric
Estonian: Muu teave Adenurici kohta
English: Adenuric is a medicine that contains the active substance febuxostat.
Estonian: Adenuric on ravim, mis sisaldab toimeainena febuksostaati.
English: In both studies, allopurinol was used at a dose of 300 mg once a day, except in patients with kidney problems, who took 100 mg.
Estonian: Mõlemas uuringus kasutati allopurinooli annuses 300 mg üks kord ööpäevas, välja arvatud neeruprobleemidega patsientidel, kelle annus oli 100 mg.
English: For more information about treatment with Adenuric, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Adenuriciga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: This is a summary of the European public assessment report (EPAR) for Adenuric.
Estonian: See on ravimi Adenuric Euroopa avaliku hindamisaruande kokkuvõte.
English: In patients with blood cancer who were undergoing chemotherapy, Adenuric was as effective as allopurinol in controlling blood levels of uric acid: in 98.3 % of patients (170 out of 173) on Adenuric blood levels of uric acid normalised compared with 96 % (166 out of 173) of patients on allopurinol.
Estonian: Keemiaravi saanud verevähiga patsientidel oli Adenuric vere kusihappesisalduse reguleerimisel sama efektiivne kui allopurinool - 98,3%-l patsientidest (170 patsiendil 173st), kes manustasid Adenuricit, normaliseerus vere kusihappesisaldus võrreldes 96%-ga allopurinooli manustanud patsientidest (166 patsiendil 173st).
English: In patients who are on chemotherapy a reduction in uric acid levels is expected to reduce the risk of tumour lysis syndrome.
Estonian: Keemiaravi saavatel patsientidel eeldatakse, et kusihappesisalduse vähenemine vähendab tuumori lüüsi sündroomi riski.
English: For the full list of all side effects and restrictions with Adenuric, see the package leaflet.
Estonian: Adenurici kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Adenuric, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Adenurici omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: For the treatment of hyperuricaemia and gout, Adenuric has been studied in two main studies involving a total of 1,834 patients.
Estonian: Hüperurikeemia ja podagra ravis uuriti Adenurici efektiivsust kahes põhiuuringus, milles osales kokku 1834 patsienti.
English: For the treatment of long-term hyperuricaemia, the recommended dose of Adenuric is 80 mg once a day.
Estonian: Pikaajalise hüperurikeemia raviks on Adenurici soovitatav annus 80 mg üks kord ööpäevas.
English: Blood uric acid levels were measured every month.
Estonian: Vere kusihappesisaldust mõõdeti üks kord kuus.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom mg once a day if blood uric acid levels remain high (above 6 mg per decilitre) after two to four weeks.
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom ööpäevas.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Adenuric.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The main measure of effectiveness was based on their blood uric acid levels.
Estonian: Efektiivsuse põhinäitaja oli nende kusihappesisaldus veres.
English: For the prevention and treatment of hyperuricaemia in patients undergoing chemotherapy, Adenuric has been studied in one main study involving 346 adult patients undergoing chemotherapy for blood cancer.
Estonian: Keemiaravi saavate patsientide hüperurikeemia ennetamisel ja ravis uuriti Adenuricit ühes põhiuuringus, milles osales 346 täiskasvanud patsienti, kes said verevähi vastu keemiaravi.
English: Keeping uric acid levels low for long enough can also shrink tophi.
Estonian: Kusihappesisalduse väiksena hoidmine piisavalt pika aja jooksul võib ka podagrasõlmi vähendada.
English: Adenuric is also used to treat and prevent high levels of uric acid in the blood in adults with blood cancers who are on chemotherapy and at risk of tumour lysis syndrome (a complication due to the breakdown of cancer cells causing a sudden rise of uric acid in the blood which can cause damage to the kidneys).
Estonian: Adenuricit kasutatakse ka vere suure kusihappesisalduse ravimiseks ja ennetamiseks verevähiga täiskasvanutel, kes saavad keemiaravi ja kellel on tuumori lüüsi sündroomi risk (vähirakkude lagunemisest tingitud tüsistus, mis põhjustab veres kusihappesisalduse äkilise suurenemise, mis võib kahjustada neerusid).
English: When this happens in the joints and causes pain, it is known as ‘gout'.
Estonian: Kui see liigestes valu tekitab, on tegu podagraga.
English: What is Adenuric?
Estonian: Mis on Adenuric?
English: Adenuric is used in patients who already have signs of a build-up of crystals, including gouty arthritis (pain and inflammation in the joints) or tophi (‘stones', larger deposits of urate crystals that can cause joint and bone damage).
Estonian: Adenuricit kasutatakse patsientidel, kellel on juba tekkinud kristallide kogunemise nähud, sealhulgas podagraartriit (liigesevalu ja -põletik) või podagrasõlmed (nn kivid ehk suuremad uraadikristallide ladestused, mis võivad kahjustada liigeseid ja luid).
English: By reducing the production of uric acid, Adenuric can reduce levels of uric acid in the blood and keep them low, stopping crystals from building up.
Estonian: Kusihappe tekke vähendamisega vähendab Adenuric vere kusihappesisaldust ja hoiab selle väiksena, peatades kristallide kogunemise.
English: The first study, carried out in 1,072 patients, compared three doses of Adenuric (80, 120 and 240 mg once a day) with placebo (a dummy treatment) and allopurinol (another medicine used to treat hyperuricaemia).
Estonian: Esimeses uuringus, milles osales 1072 patsienti, võrreldi Adenurici kolme annust (80 mg, 120 mg ja 240 mg üks kord ööpäevas) platseebo (näiva ravimi) ja allopurinooliga (samuti hüperurikeemia ravim).
English: The CHMP concluded that Adenuric was more effective than allopurinol at lowering blood uric acid levels including in patients undergoing chemotherapy , but that it could carry a greater risk of side effects affecting the heart and blood vessels.
Estonian: Inimravimite komitee järeldas, et Adenuric vähendab vere kusihappesisaldust allopurinoolist efektiivsemalt, sh keemiaravi saavatel patsientidel, kuid ravimiga võib kaasneda suurem südame ja veresoonkonnaga seotud kõrvalnähtude risk.
English: Why has Adenuric been approved?
Estonian: Miks Adenuric heaks kiideti?
English: What is the risk associated with Adenuric?
Estonian: Mis riskid Adenuriciga kaasnevad?
English: For the prevention and treatment of hyperuricaemia in patients undergoing chemotherapy, the recommended dose is 120 mg once a day.
Estonian: Keemiaravi saavate patsientide hüperurikeemia ennetamiseks ja raviks on soovitatav annus 120 mg üks kord ööpäevas.
English: The most commonly reported side effects with Adenuric are gout flare-ups, abnormal liver test results, diarrhoea, nausea (feeling sick), headache, rash and oedema (swelling).
Estonian: Adenurici kõige sagedamad kõrvalnähud on podagra ägenemine, maksaensüümide ebanormaalne sisaldus veres, kõhulahtisus, iiveldus, peavalu, lööve ja turse.
English: In the first study, 48% of the patients taking 80 mg Adenuric once a day (126 out of 262) and 65% of the patients taking 120 mg once a day (175 out of 269) had levels of uric acid below 6 mg/dl in the final three measurements.
Estonian: Esimeses uuringus oli vere kusihappesisaldus kolmel viimasel mõõtmisel alla 6 mg/dl 48%-l patsientidest (126 patsienti 262st), kes said 80 mg Adenuricit üks kord ööpäevas, ja 65%-l patsientidest (175 patsienti 269st), kes said 120 mg Adenuricit üks kord ööpäevas.
English: This was compared with 22% of the patients taking allopurinol (60 out of 268) and none of the 134 patients taking placebo.
Estonian: Allopurinooli kasutanud patsientide seas oli sama tulemusega patsientide osakaal 22% (60 patsienti 268st) ja platseebot kasutanud 134 patsiendi seas 0%.
English: Adenuric is used to treat adults with long-term hyperuricaemia (high levels of uric acid or ‘urate' in the blood).
Estonian: Adenuricit kasutatakse kroonilise (pikaajalise) hüperurikeemia (suur kusihappesisaldus veres) raviks täiskasvanutel.
English: Adenuric treatment should not be stopped if an attack of gout occurs.
Estonian: Ravi Adenuriciga ei tohi podagrahoo tekkimisel katkestada.
English: The second study compared two doses of Adenuric (80 and 120 mg once a day) with allopurinol over one year in 762 patients.
Estonian: Teises uuringus, milles osales 762 patsienti, võrreldi Adenurici kaht annust (80 mg ja 120 mg üks kord ööpäevas) allopurinooliga ühe aasta jooksul.
English: What benefit has Adenuric shown during the studies?
Estonian: Milles seisneb uuringute põhjal Adenurici kasulikkus?
English: How does Adenuric work?
Estonian: Kuidas Adenuric toimib?
English: This usually reduces blood uric acid levels within two weeks, but the dose can be increased to 120
Estonian: Tavaliselt vähendab Adenuric vere kusihappesisaldust kahe nädalaga, ent kui vere kusihappesisaldus on kahe kuni nelja nädala pärast endiselt suur (üle 6 mg/dl), võib annust suurendada 120 mg-ni üks kord
English: The active substance in Adenuric, febuxostat, reduces the formation of uric acid.
Estonian: Adenurici toimeaine febuksostaat vähendab kusihappe teket.
English: Rare serious hypersensitivity (allergic) reactions to Adenuric have occurred post-marketing.
Estonian: Ravimi turuletuleku järel on täheldatud harvaesinevaid raskeid ülitundlikkusreaktsioone (allergilisi reaktsioone).
English: How is Adenuric used?
Estonian: Kuidas Adenuricit kasutatakse?
English: What is Adenuric used for?
Estonian: Milleks Adenuricit kasutatakse?
English: Adenuric was more effective than allopurinol and placebo in treating hyperuricaemia by reducing blood uric acid levels.
Estonian: Hüperurikeemia ravis vähendas Adenuric vere kusihappesisaldust efektiivsemalt kui allopurinool ja platseebo.
English: How has Adenuric been studied?
Estonian: Kuidas Adenuricit uuriti?
English: Make sure you do the following:
Estonian: Veenduge, et toimite järgmiselt.
English: FREQUENCY NOT KNOWN
Estonian: SAGEDUS TEADMATA
English: This medicine could seriously harm your baby.
Estonian: See ravim võib teie lapsele põhjustada raskeid kahjustusi.
English: It is very important for you to keep all of these appointments.
Estonian: On väga tähtis, et käite kõigil visiitidel.
English: − This medicine has been prescribed for you only.
Estonian: − Ravim on välja kirjutatud üksnes teile.
English: Driving and using machines Not relevant.
Estonian: Autojuhtimine ja masinatega töötamine Pole asjakohane.
English: The elimination half-life in most patients is 2 to 3 hours.
Estonian: Eliminatsiooni poolväärtusaeg on enamikul patsientidest 2 - 3 tundi.
English: Ask your doctor which method is best for you.
Estonian: Küsige arsti käest, missugune meetod teile sobib.
English: Date of latest renewal: 21 September 2009
Estonian: Müügiloa viimase uuendamise kuupäev: 21. september 2009
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 25 August 1999
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Esmase müügiloa väljastamise kuupäev: 25. august 1999
English: Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including medicines obtained without a prescription.
Estonian: Teatage oma arstile või apteekrile, kui te kasutate, olete hiljuti kasutanud või kavatsete kasutada mis tahes muid ravimeid, kaasa arvatud ilma retseptita ostetud ravimeid.
English: 2333 CN Leiden Netherlands
Estonian: 2333 CN Leiden Holland
English: Even though agranulocytosis only affects 1 to 2 out of 100 users, it is important to monitor your blood on a regular basis.
Estonian: Kuigi agranulotsütoos esineb ainult 1-2 kasutajal 100-st, on tähtis teie verd korrapäraselt jälgida.
English: There are no adequate data from the use of deferiprone in pregnant women.
Estonian: Piisavad andmed deferiprooni kasutamise kohta rasedatel naistel puuduvad.
English: Adverse reaction frequencies: Very common (≥1/10), Common (≥1/100 to <1/10), not known (cannot be estimated from the available data).
Estonian: Kõrvaltoimete sagedused: Väga sage (≥1/10), Sage (≥1/100 kuni <1/10), teadmata (ei saa hinnata olemasolevate andmete alusel).
English: These women should be advised to take contraceptive measures and must be advised to immediately stop taking deferiprone if they become pregnant or plan to become pregnant (see section 4.3).
Estonian: Naistele tuleb soovitada rasestumisvastaste meetmete kasutamist ja lõpetada kohe deferiprooni tarvitamine, kui nad rasestuvad või plaanivad rasestuda (vt lõik 4.3).
English: • Whenever the risk management system is modified, especially as a result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
Estonian: • kui muudetakse riskijuhtimissüsteemi, eriti kui saadakse uut teavet, mis võib oluliselt mõjutada riski/kasu suhet, või kui saavutatakse oluline (ravimiohutuse või riski minimeerimise) eesmärk.
English: − if you are HIV positive or if your liver or kidney function is severely impaired, your doctor may recommend additional tests.
Estonian: − Kui te olete HIV-positiivne või kui teie maksa-või neerutalitlus on tõsiselt halvenenud , võib arst soovitada täiendavaid analüüse.
English: PATIENT/CARER REMINDER CARD ((Front Cover))
Estonian: PATSIENDI / PATSIENDI HOOLDAJA MEELESPEA ((Front Cover))
English: • To warn women of childbearing age to not become pregnant because deferiprone may seriously harm the unborn baby.
Estonian: • hoiatada fertiilses eas naisi rasestumise eest, sest deferiproon võib tõsiselt kahjustada sündimata last.
English: Store in the original package in order to protect from light.
Estonian: Säilitada originaalpakendis, et kaitsta toodet valguse eest.
English: - Pregnancy (see section 4.6).
Estonian: - Rasedus (vt lõik 4.6).
English: The neutrophil count should be then monitored more frequently.
Estonian: Seejärel tuleb neutrofiilide arvu sagedamini jälgida.
English: ANNEX II A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Estonian: LISA II A. RAVIMIPARTII KASUTAMISEKS VABASTAMISE EEST VASTUTAV TOOTJA B. HANKE- JA KASUTUSTINGIMUSED VÕI PIIRANGUD C. MÜÜGILOA MUUD TINGIMUSED JA NÕUDED D. RAVIMPREPARAADI OHUTU JA EFEKTIIVSE KASUTAMISE TINGIMUSED JA PIIRANGUD
English: Keizersgracht 311 1016 EE Amsterdam Netherlands
Estonian: Keizersgracht 311 1016 EE Amsterdam Holland
English: The Patient/Carer reminder card shall contain the following key messages:
Estonian: Patsiendi/hooldaja meeldetuletuskaart peab sisaldama järgmisi olulisi märkusi:
English: Hypromellose 2910 USP/EP
Estonian: Hüpromelloos 2910 USP/EP Hüdroksüpropüültselluloos Makrogool
English: - History of recurrent episodes of neutropenia.
Estonian: - Anamneesis korduvad neutropeenia episoodid.
English: Non-clinical studies have been conducted in animal species including mice, rats, rabbits, dogs and monkeys.
Estonian: Mittekliinilisi uuringuid on läbi viidud hiirte, rottide, küülikute, koerte ja ahvidega.
English: A total daily dose above 100 mg/kg body weight is not recommended because of the potentially increased risk of adverse reactions (see sections 4.4, 4.8, and 4.9).
Estonian: Ööpäevast koguannust üle 100 mg/kg kehakaalu kohta ei soovitata kõrvaltoimete riski võimaliku suurenemise tõttu (vt lõik 4.4, 4.8 ja 4.9).
English: Deferiprone did not show direct mutagenic properties; however, it did display clastogenic characteristics in in vitro assays and in animals.
Estonian: Deferiproon ei näidanud otseseid mutageenseid omadusi; kuid see näitas klastogeensed omadusi in vitro uuringutes ja loomadel
English: SYSTEM ORGAN CLASS VERY COMMON
Estonian: ORGANSÜSTEEMI KLASS
English: − if you are allergic to deferiprone or any of the other ingredients of this medicine (listed in section 6).
Estonian: − kui olete deferiprooni või selle ravimi mis tahes koostisosade (loetletud lõigus 6) suhtes allergiline;
English: If taken during pregnancy, Ferriprox may seriously harm the unborn baby.
Estonian: Raseduse ajal kasutades võib Ferriprox põhjustada raskeid kahjustusi teie sündimata lapsele.
English: Data from pooled clinical studies in patients with systemic iron overload show that 63% of the episodes of agranulocytosis occurred within the first six months of treatment, 74% within the first year and 26% after one year of therapy.
Estonian: Süsteemse raualiiaga patsientidel läbiviidud kliiniliste uuringute koondandmed näitavad, et 63% agranulotsütoosi episoodidest tekkis esimese kuue ravikuu jooksul, 74% esimese aasta jooksul ja 26% ühe aasta jooksul pärast ravi.
English: The neurological disorders progressively regressed after deferiprone discontinuation.
Estonian: Neuroloogilised häired taandusid järk-järgult pärast deferiproonravi lõpetamist.
English: Do not take this medicine if you are pregnant or if you are trying to become pregnant.
Estonian: Ärge võtke seda ravimit, kui olete rase või soovite rasestuda.
English: Cardiac endpoints were assessed by echocardiogram, electrocardiogram, the New York Heart Association classification and death due to cardiac disease.
Estonian: Kardiaalseid tulemusnäitajaid hinnati ehhokardiogrammi, elektrokardiogrammi, New Yorgi Südameliidu klassifikatsiooni ning südamehaigusest põhjustatud surmajuhtumite põhjal.
English: If treatment is unavoidable, breast-feeding must be stopped (see section 4.3).
Estonian: Kui ravi on vältimatu, tuleb imetamine lõpetada (vt lõik 4.3).
English: However, chelation therapy may not necessarily protect against iron-induced organ damage.
Estonian: Kuid rauakelaatide moodustumine ei pruugi vältida rauast tingitud organkahjustusi.
English: Systemic exposure to the inactive 3-O-glucuronide increased with decreasing eGFR.
Estonian: Inaktiivse 3-O-glükuroniidi süsteemne ekspositsioon suurenes eGFR vähenemisega.
English: No prenatal and postnatal reproductive studies have been conducted in animals.
Estonian: Pre- ja postnataalseid reproduktiivseid uuringuid loomadel tehtud ei ole.
English: Your white blood cell count must be checked within 24 hours in order to detect potential agranulocytosis.
Estonian: Teie vere valgeliblede arvu tuleb kontrollida 24 tunni jooksul, võimaliku agranulotsütoosi avastamiseks.
English: Gastrointestinal effects are more frequent at the beginning of therapy and resolve in most patients within a few weeks without the discontinuation of treatment.
Estonian: Gastrointestinaalsed kõrvalnähud esinevad sagedamini deferiproonravi alguses ja taanduvad enamusel patsientidest mõne nädala jooksul ravi katkestamata.
English: • To increase patient awareness of the significance of any symptoms of infection while taking deferiprone
Estonian: • suurendada patsientide teadlikkust mis tahes infektsiooni sümptomite tähtsuse osas deferiprooni võtmise ajal;
English: Increased Appetite
Estonian: Suurenenud söögiisu
English: In addition he or she might ask you to undergo liver biopsies.
Estonian: Lisaks võib ta paluda Teil käia maksabiopsias.
English: 1016 EE Amsterdam Netherlands
Estonian: 1016 EE Amsterdam Holland
English: Not known (frequency cannot be estimated from the available data): − allergic reactions including skin rash or hives
Estonian: Teadmata (sagedust ei ole võimalik olemasolevate andmete põhjal hinnata): - allergilised reaktsioonid, sealhulgas nahalööve ja nõgestõbi.
English: Less severe episodes of neutropenia were reported in approximately 5% of patients.
Estonian: Vähemtõsiseid neutropeeniajuhte täheldati u 5% patsientidest.
English: Women of childbearing potential must be advised to avoid pregnancy due to the clastogenic and teratogenic properties of the medicinal product.
Estonian: Viljakas eas naistel soovitatakse ravimi klastogeensete ja teratogeensete omaduste tõttu rasedust vältida.
English: The response to therapy should be assessed periodically, and the occurrence of adverse events closely monitored.
Estonian: Ravivastust tuleb hinnata periooodiliselt ning kõrvalnähtude ilmnemisel neid tähelepanelikult jälgida.
English: • To increase patient awareness of the importance of regular monitoring of the neutrophil count during treatment with deferiprone
Estonian: • suurendada patsientide teadlikkust neutrofiilide arvu regulaarse jälgimise tähtsuse osas deferiprooniga ravi ajal;
English: Number of tablets (three times/day)
Estonian: Tablettide arv (3 korda ööpäevas)
English: A low white blood cell count can be associated with a serious and potentially life-threatening infection.
Estonian: Vere valgeliblede madalat taset võib seostada tõsise ja potentsiaalselt eluohtliku infektsiooniga.
English: Do not use this medicine after the expiry date which is stated on the carton and the label after EXP. After first opening use within 35 days.
Estonian: Ärge kasutage seda ravimit pärast kõlblikkusaega, mis on märgitud sildil ja karbil pärast EXP. Pärast esmast avamist kasutada 35 päeva jooksul.
English: Ferriprox will be most effective if you do not miss any doses.
Estonian: Ferriprox toimib kõige efektiivsemalt siis, kui te ei unusta ühtegi annust võtmata.
English: If you become pregnant while taking Ferriprox, stop taking the medicine immediately and tell your doctor.
Estonian: Kui rasestute Ferriproxi kasutamise ajal, lõpetage ravimi kasutamine koheselt ja rääkige sellest oma arstile.
English: The safety of concurrent use of deferiprone and vitamin C has not been formally studied.
Estonian: Deferiprooni ja vitamiin C samaaegse kasutamise ohutust ei ole uuritud.
English: *number of tablets rounded to nearest half tablet
Estonian: *tablettide arv ümardatuna lähima pooltabletini
English: In clinical trials, weekly monitoring of the neutrophil count has been effective in identifying cases of neutropenia and agranulocytosis.
Estonian: Kliinilistes uuringutes on neutrofiilide arvu iganädalane jälgimine olnud efektiivne neutropeenia ja agranulotsütoosi juhtude tuvastamisel.
English: − if you are pregnant or breast-feeding.
Estonian: − kui olete rase või imetate last.